Development of quality standards for multi-center, longitudinal magnetic resonance imaging studies in clinical neuroscience

Magnetic resonance imaging (MRI) data is generated by a complex procedure. Many possible sources of error exist which can lead to a worse signal. For example, hidden defective components of a MRI-scanner, changes in the static magnetic field caused by a person simply moving in the MRI scanner room as well as changes in the measurement sequences can negatively affect the signal-to-noise ratio (SNR). A comprehensive, reproducible, quality assurance (QA) procedure is necessary, to ensure reproducible results both from the MRI equipment and the human operator of the equipment. To examine the quality of the MRI data, there are two possibilities. On the one hand, water or gel-filled objects, so-called "phantoms", are regularly measured. Based on this signal, which in the best case should always be stable, the general performance of the MRI scanner can be tested. On the other hand, the actually interesting data, mostly human data, are checked directly for certain signal parameters (e.g., SNR, motion parameters). This thesis consists of two parts. In the first part a study-specific QA-protocol was developed for a large multicenter MRI-study, FOR2107. The aim of FOR2107 is to investigate the causes and course of affective disorders, unipolar depression and bipolar disorders, taking clinical and neurobiological effects into account. The main aspect of FOR2107 is the MRI-measurement of more than 2000 subjects in a longitudinal design (currently repeated measurements after 2 years, further measurements planned after 5 years). To bring MRI-data and disease history together, MRI-data must provide stable results over the course of the study. Ensuring this stability is dealt with in this part of the work. An extensive QA, based on phantom measurements, human data analysis, protocol compliance testing, etc., was set up. In addition to the development of parameters for the characterization of MRI-data, the used QA-protocols were improved during the study. The differences between sites and the impact of these differences on human data analysis were analyzed. The comprehensive quality assurance for the FOR2107 study showed significant differences in MRI-signal (for human and phantom data) between the centers. Occurring problems could easily be recognized in time and be corrected, and must be included for current and future analyses of human data. For the second part of this thesis, a QA-protocol (and the freely available associated software "LAB-QA2GO") has been developed and tested, and can be used for individual studies or to control the quality of an MRI-scanner. This routine was developed because at many sites and in many studies, no explicit QA is performed nevertheless suitable, freely available QA-software for MRI-measurements is available. With LAB-QA2GO, it is possible to set up a QA-protocol for an MRI-scanner or a study without much effort and IT knowledge. Both parts of the thesis deal with the implementation of QA-procedures. High quality data and study results can be achieved only by the usage of appropriate QA-procedures, as presented in this work. Therefore, QA-measures should be implemented at all levels of a project and should be implemented permanently in project and evaluation routines

Effects of Short Term Adiponectin Receptor Agonism on Cardiac Function and Energetics in Diabetic db/db Mice.

Objective Impaired cardiac efficiency is a hallmark of diabetic cardiomyopathy in models of type 2 diabetes. Adiponectin receptor 1 (AdipoR1) deficiency impairs cardiac efficiency in non-diabetic mice, suggesting that hypoadiponectinemia in type 2 diabetes may contribute to impaired cardiac efficiency due to compromised AdipoR1 signaling. Thus, we investigated whether targeting cardiac adiponectin receptors may improve cardiac function and energetics, and attenuate diabetic cardiomyopathy in type 2 diabetic mice. Methods A non-selective adiponectin receptor agonist, AdipoRon, and vehicle were injected intraperitoneally into Eight-week-old db/db or C57BLKS/J mice for 10 days. Cardiac morphology and function were evaluated by echocardiography and working heart perfusions. Results Based on echocardiography, AdipoRon treatment did not alter ejection fraction, left ventricular diameters or left ventricular wall thickness in db/db mice compared to vehicle-treated mice. In isolated working hearts, an impairment in cardiac output and efficiency in db/db mice was not improved by AdipoRon. Mitochondrial respiratory capacity, respiration in the presence of oligomycin, and 4-hydroxynonenal levels were similar among all groups. However, AdipoRon induced a marked shift in the substrate oxidation pattern in db/db mice towards increased reliance on glucose utilization. In parallel, the diabetes-associated increase in serum triglyceride levels in vehicle-treated db/db mice was blunted by AdipoRon treatment, while an increase in myocardial triglycerides in vehicle-treated db/db mice was not altered by AdipoRon treatment. Conclusion AdipoRon treatment shifts myocardial substrate preference towards increased glucose utilization, likely by decreasing fatty acid delivery to the heart, but was not sufficient to improve cardiac output and efficiency in db/db mice

Quality Assurance for functional Magnetic Resonance Imaging

This poster was presented at the OHBM 2016 in Geneva (posternumber: #1696). It describes the introduction of a phantomholder for gel phantom quality assurance to control the stability of the magnetic resonance (MR) signal. Using the phantom holder reduces the variance of the QA metrics and helps the user to detect outlier (or possible MR malfunction) much easier. <br

Development of quality standards for multi-center, longitudinal magnetic resonance imaging studies in clinical neuroscience

Magnetic resonance imaging (MRI) data is generated by a complex procedure. Many possible sources of error exist which can lead to a worse signal. For example, hidden defective components of a MRI-scanner, changes in the static magnetic field caused by a person simply moving in the MRI scanner room as well as changes in the measurement sequences can negatively affect the signal-to-noise ratio (SNR). A comprehensive, reproducible, quality assurance (QA) procedure is necessary, to ensure reproducible results both from the MRI equipment and the human operator of the equipment. To examine the quality of the MRI data, there are two possibilities. On the one hand, water or gel-filled objects, so-called "phantoms", are regularly measured. Based on this signal, which in the best case should always be stable, the general performance of the MRI scanner can be tested. On the other hand, the actually interesting data, mostly human data, are checked directly for certain signal parameters (e.g., SNR, motion parameters). This thesis consists of two parts. In the first part a study-specific QA-protocol was developed for a large multicenter MRI-study, FOR2107. The aim of FOR2107 is to investigate the causes and course of affective disorders, unipolar depression and bipolar disorders, taking clinical and neurobiological effects into account. The main aspect of FOR2107 is the MRI-measurement of more than 2000 subjects in a longitudinal design (currently repeated measurements after 2 years, further measurements planned after 5 years). To bring MRI-data and disease history together, MRI-data must provide stable results over the course of the study. Ensuring this stability is dealt with in this part of the work. An extensive QA, based on phantom measurements, human data analysis, protocol compliance testing, etc., was set up. In addition to the development of parameters for the characterization of MRI-data, the used QA-protocols were improved during the study. The differences between sites and the impact of these differences on human data analysis were analyzed. The comprehensive quality assurance for the FOR2107 study showed significant differences in MRI-signal (for human and phantom data) between the centers. Occurring problems could easily be recognized in time and be corrected, and must be included for current and future analyses of human data. For the second part of this thesis, a QA-protocol (and the freely available associated software "LAB-QA2GO") has been developed and tested, and can be used for individual studies or to control the quality of an MRI-scanner. This routine was developed because at many sites and in many studies, no explicit QA is performed nevertheless suitable, freely available QA-software for MRI-measurements is available. With LAB-QA2GO, it is possible to set up a QA-protocol for an MRI-scanner or a study without much effort and IT knowledge. Both parts of the thesis deal with the implementation of QA-procedures. High quality data and study results can be achieved only by the usage of appropriate QA-procedures, as presented in this work. Therefore, QA-measures should be implemented at all levels of a project and should be implemented permanently in project and evaluation routines

Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-b Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy

We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-b activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despit

Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation, Inflammation and Angiogenesis in Chronic Allograft Nephropathy

We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature

Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis in chronic allograft nephropathy.

We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature

The mTOR Inhibitor Everolimus Attenuates the Time Course of Chronic Anti-Thy1 Nephritis in the Rat

Background: The antiproliferative immunosuppressant everolimus adversely affects the acute reversible anti-Thy1 nephritis model. We hypothesized that everolimus treatment started after the acute proliferative phase could even be beneficial in the chronic anti-Thy1 nephritis model in the rat. Methods: Chronic anti-Thy1 nephritis was induced by injection of the monoclonal antibody 1-22-3 in 20 male Sprague-Dawley rats 7 days after uninephrectomy. Two weeks after disease induction, rats were randomly treated with either everolimus or vehicle for 14 weeks. Changes in progression of renal disease were investigated by immunohistochemistry and real-time PCR 16 weeks after disease induction. Results: During chronic anti-Thy1 nephritis, the formation of focal segmental glomerulosclerosis lesions, the degree of interstitial fibrosis as well as the increase in proteinuria over 14 weeks was ameliorated by everolimus treatment. Increased glomerular hypertrophy observed in the vehicle-treated rats was completely prevented in the everolimus- treated nephritic rats. Increased glomerular fibronectin mRNA and protein as well as the renal influx of monocytes/ macrophages was significantly reduced in the evero- limus group. Everolimus reduced the pro-angiogenic factor vascular endothelial growth factor (VEGF) and VEGF mRNA in glomeruli, while the transforming growth factor- _ signaling pathway was not affected. Conclusion: ‘Late’ start of everolimus treatment demonstrates beneficial effects on the time course of chronic anti-Thy1 nephritis

Predicting bipolar risk scores using the volumes of hippocampal subfields and nuclei of the amygdala with a machine learning approach

Bipolar disorders (BD) are serious chronic mental disorders. 10-20% of patients suffering from BD commit suicide throughout their disease course (Müller-Oerlinghausen et al. 2002). A longer duration of untreated illness leads to more depressive and manic episodes and more suicidal behavior (Drancourt et al. 2013). Hence, early detection and treatment is crucial. Some attempts to detect BD ahead of diagnosis have already been made. For instance, the prognostic accuracy of two clinical interviews has been investigated: The Bipolar at Risk States Revised (BARS; Harrell's C = 0.777) and the Semistructured Interview of At Risk Bipolar States (SIBARS; Harrell's C = 0.742) (Fusar-Poli et al. 2018). Also, in a genetic study, polygenic risk scores differed significantly between control and at-risk groups, but not between at-risk and BD type-I groups (Smigielski et al. 2021). Adding additional data categories to the scales, in particular neuroimaging, could increase the prognostic accuracy and thus lead to an earlier illness detection and better clinical outcomes. With the aim of finding a valid biomarker for BD using neuroimaging, several structural abnormalities have already been identified (Arnone et al. 2009). A currently published mega-analysis with 4,698 participants comparing BD patients with healthy controls (HCs) found significantly smaller volumes of the hippocampus and its subfields (whole hippocampus, GC ML DG, CA4, CA3, CA1, subiculum, presubiculum, molecular layer HP, HATA and hippocampal tail) but not for other subfields (parasubiculum, fimbria and the hippocampal fissure) (Haukvik et al. 2022). Another study found some subfields to be smaller for both, BD and schizophrenia patients, compared to HCs (bilateral CA2/3, CA4/dentate gyrus, subiculum and right CA1) (Haukvik et al. 2015). Meanwhile, presubiculum volumes were smaller only in schizophrenia and, comparing schizophrenia with BD directly, the bilateral subiculum as well as the right presubiculum was found to be smaller for schizophrenia (Haukvik et al. 2015). In an investigation between different psychotic disorders, smaller subfield volumes could be found only in the bilateral CA2/3, the left presubiculum and the right CA4/DG, comparing psychotic bipolar disorder (Mathew et al. 2014). Now, we will investigate if there are observable differences already before any BD diagnosis. Another potentially interesting region for early detection of BD, with less literature to date, is the amygdala and its subnuclei. For instance, a decreased volume was found for the lateral and cortical nuclei, but not for the basal and accessory basal nuclei in BD patients compared to HC (Pantazopoulos et al. 2017). However, Bielau et al. (2005) found no significant differences for the whole amygdala volume in a post-mortem study between BD patients and HC. Thus, the volumes of segmented amygdala nuclei volumes should be considered as potential risk factors for BD. While traditional statistical group comparisons can show mean structural abnormalities, they lack practical clinical impact (Orru et al. 2012). A multivariable machine learning (ML) approach meanwhile allows to make individual inferences potentially useful in clinical prognostics. Thus, we will implement a support vector machine (SVM). This is a widely used algorithm, which classifies huge datasets into groups through weighting so-called features, i.e. structural volumes. These groups are here defined as risk states for BD through three independent assessment tools: EPIbipolar (Leopold et al. 2012), BPSS-P (Correll et al. 2014) and SIBARS (Fusar-Poli et al. 2018). In a currently submitted paper, we already investigated such a SVM classification. We used regional cortical thickness and surface area values as well as subcortical structural volumes (Mikolas et al. 2022), in submission, pre-registered at https://osf.io/c4hfn). Now, we will adapt this procedure to hippocampal subfields and nuclei of the amygdala